1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
CellaVision AB

CellaVision AB

15.12
EUR
+0.22
(+1.48%)
0.49EPS
25.17P/E
293.37MMarket Cap
Oct 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.54
9.09
10.04
11.11
12.97
15.29
19.36
19.77
23.71
26.8
28.4
30.32
31.82
30.99
Basic EPS, GAAP
0.79
1.32
2.21
2.51
2.92
3.72
4.16
3.75
5.25
4.96
5.46
5.9
6.42
5.41
Free Cash Flow per Basic Share
0.65
1.09
3.3
2.57
2.47
2.92
5.17
2.64
6.7
5.76
8.24
8.32
8.41
7.24
Dividend per Share
0.4
0.5
1
1.5
1.5
1.5
1.5
- -
0.75
2
2.25
2.25
2.5
2.75
Book Value per Share
5.56
6.34
7.69
8.64
10.1
12.17
14.61
18.01
22.78
26.9
30.04
34.2
37.21
37.14
Tangible Book Value per Share
4.45
5.2
6.46
7.19
7.85
9.33
2.04
5.4
7.76
10.16
11.87
13.76
15.04
14.11
Basic Weighted Avg Shares
24
24
24
24
24
24
24
24
24
24
24
24
24
24
Sales/Revenue/Turnover
180
217
239
265
309
365
462
471
566
639
677
723
759
739
Operating Margin (%)
14.43
19.74
27.35
27.98
29.39
30.59
27.41
23.39
28.77
24.75
24.66
24.57
26.62
22.23
Depreciation Expense
9
13
8
8
8
7
20
32
33
40
40
41
40
- -
Net Income, GAAP
19
31
53
60
70
89
99
89
125
118
130
141
153
129
Effective Tax Rate (%)
23.32
27.45
19.42
21.08
22.82
20.88
23.25
20.27
20.82
20.28
20.65
20.43
21.2
20.97
Profit Margin (%)
10.53
14.51
22.07
22.56
22.54
24.31
21.48
18.98
22.16
18.51
19.24
19.46
20.17
17.46
Working Capital
70
98
140
167
188
223
139
194
230
244
246
294
330
305
LT Debt
- -
- -
- -
- -
- -
- -
123
87
96
60
29
13
12
36
Total Equity
133
151
184
206
241
290
348
430
543
642
716
816
888
886
Return on Invested Capital (%)
13.64
20.13
30.97
29.68
31.02
32.85
23.69
16.17
20.7
17.69
17.37
17.41
18.14
14.5
Return on Capital (%)
13.15
20.64
31.01
30.32
30.87
33.04
24.55
16.88
20.42
16.88
17.43
17.52
17.52
14.62
Return on Common Equity (%)
14.71
22.17
31.55
30.69
31.19
33.39
31.05
23
25.77
19.97
19.19
18.37
17.97
15.11

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
14
12
16
LT Borrowings
12
10
36
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
3,705
3,661
3,250

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
441
472
437
Cash, Cash Equivalents & STI
188
230
172
Accounts Receivable, Net
120
91
113
Inventories
112
122
129
Total Current Liabilities
111
124
132
Payables & Accruals
- -
- -
- -
ST Debt
14
12
16
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.19%
15.78%
8.81%
Free Cash Flow
20.5%
36.94%
1.06%
Net Income, GAAP
12.04%
12.27%
8.78%
Sales/Revenue/Turnover
12.47%
10.13%
4.94%
Total Cash Common Dividend
- -
- -
11.11%

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
170
188
179
187
723
2025
195
191
176
197
759
2026
166
200
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.26
1.62
1.3
1.72
5.9
2025
1.74
1.58
1.31
1.79
6.42
2026
0.94
1.37
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
2.25
- -
- -
2.25
2025
- -
2.5
- -
- -
2.5
2026
- -
2.75
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Steve Ferguson
Full Time Employees
251
Sector
Health technology
Industry
Medical specialties
Address
Mobilvägen 12 Lund SN Sweden 223 62
IPO Date
May 28, 2007
Website
cellavision.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
CellaVision AB (publ) (CEVI.ST) develops and markets digital hematology microscopy solutions that automate the analysis of blood and body fluid samples for laboratories worldwide; core products include advanced analyzers such as the DI-60 for high-throughput large labs and the DC-1 compact system for small and medium-sized facilities, reagents encompassing staining protocols, smear makers and stainers like RAL SmearBox and RAL StainBox, and software platforms for image analysis, remote access, competency testing, and artificial intelligence-driven cell classification. The company manufactures reagents in-house at its facility in Martillac, France, with analyzer production outsourced in Sweden. Founded in 1994 and headquartered in Lund, Sweden, CellaVision employs over 230 staff, maintains market support offices in 16 countries including the US, Canada, Japan, China, and several European and Asian markets, and serves over 40 countries through global partners, targeting healthcare providers handling human and veterinary samples. CellaVision integrates hardware, software, and consumables into a recurring revenue model bolstered by its 2019 acquisition of RAL Diagnostics, which expanded sample preparation capabilities in hematology, microbiology, cytology, and pathology while adding vertical integration for quality control and new revenue streams. In 2024, the company marked 30 years of operations with sales reaching SEK 723 million and reported 14% organic growth in Q1 2025 driven by instrument sales in EMEA, alongside ongoing expansions like enhanced alliances such as with Sysmex Corporation to advance diagnostic technologies. Recent activities include the May 2025 Annual General Meeting approving a SEK 2.50 per share dividend, board re-elections, and share repurchase authorizations, reflecting sustained strategic focus on innovation and market penetration.